Flu Vaccine Cut Hospitalizations Despite Drifted H3N2 Strain - Scorecard - MDSpire

Flu Vaccine Cut Hospitalizations Despite Drifted H3N2 Strain

Interim CDC estimates found the 2025–2026 vaccine reduced outpatient influenza visits by up to 41% and hospitalizations by up to 41%.

  • By

  • Kerri Miller

  • March 17, 2026

  • 5 min

Share

Clinical Scorecard: Flu Vaccine Cut Hospitalizations Despite Drifted H3N2 Strain

At a Glance

CategoryDetail
Condition
Key MechanismsVaccination reduces morbidity associated with influenza infections, with effectiveness estimates ranging from 22% to 41%.
Target Population
Care Setting

Key Highlights

  • Pediatric patients showed the strongest protection with hospitalization effectiveness at 38% to 41%.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

        • Consider potential unmeasured confounding factors in effectiveness studies, especially with antigenic drift.

        Patient & Prescribing Data

        Vaccination is crucial even with antigenic drift in circulating viruses; pediatric effectiveness estimates range from 38% to 41%.

        Clinical Best Practices

        • Encourage vaccination for all eligible persons aged 6 months and older.
        • Document vaccination status accurately to avoid misclassification.
        • Monitor for unmeasured confounding factors in effectiveness studies.

        References

        Original Source(s)

        Flu Vaccine Cut Hospitalizations Despite Drifted H3N2 Strain

        • by Kerri Miller

        • March 17, 2026

        Related Content

        FDA Expands Afrezza to Pediatric Diabetes

        The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.

        Retatrutide Shows 28% Weight Loss in Phase 3 Trial

        Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

        FDA Monthly Preview: Key June Decisions to Watch

        Several FDA decisions across multiple specialties are expected this month.